Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (561-570 of 1,058) with videos related to

Pageof 106
Sort By:
Blood|March 18, 2006
FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathwaysLatha P Ganesan, Trupti Joshi, Huiqing Fang, et al.
Cancer Research|February 19, 2008
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signalingJui-Hsiang Hung, Yen-Shen Lu, Yu-Chieh Wang, et al.
Leukemia|February 11, 2022
Clonal hematopoiesis of indeterminate potential in the companion dogKimberley Sebastian, H Gülçin Özer, Cory Howard, et al.
Cancer Research Communications|December 24, 2021
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A InhibitionEric D Eisenmann, Qiang Fu, Elizabeth M Muhowski, et al.
Clinical Proteomics|September 1, 2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cellsRajbir Singh, Sean W Harshman, Amy S Ruppert, et al.
Molecular Pharmaceutics|May 12, 2012
Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivityHongyan Wang, Ming Chiu, Zhiliang Xie, et al.
Biochemistry|June 1, 2018
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated DegradationAlexandru D Buhimschi, Haley A Armstrong, Momar Toure, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
British Journal of Haematology|September 19, 2019
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinibElizabeth M Kander, Qiuhong Zhao, Seema A Bhat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Pentostatin in steroid-refractory acute graft-versus-host diseaseJavier Bolaños-Meade, David A Jacobsohn, Jeffrey Margolis, et al.
Pageof 106

Showing results (561-570 of 1,058) with videos related to

Sort By:
Pageof 106
Blood|March 18, 2006
FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathwaysLatha P Ganesan, Trupti Joshi, Huiqing Fang, et al.
Cancer Research|February 19, 2008
FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signalingJui-Hsiang Hung, Yen-Shen Lu, Yu-Chieh Wang, et al.
Leukemia|February 11, 2022
Clonal hematopoiesis of indeterminate potential in the companion dogKimberley Sebastian, H Gülçin Özer, Cory Howard, et al.
Cancer Research Communications|December 24, 2021
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A InhibitionEric D Eisenmann, Qiang Fu, Elizabeth M Muhowski, et al.
Clinical Proteomics|September 1, 2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cellsRajbir Singh, Sean W Harshman, Amy S Ruppert, et al.
Molecular Pharmaceutics|May 12, 2012
Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivityHongyan Wang, Ming Chiu, Zhiliang Xie, et al.
Biochemistry|June 1, 2018
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated DegradationAlexandru D Buhimschi, Haley A Armstrong, Momar Toure, et al.
Blood Advances|April 19, 2024
Acalabrutinib-based regimens in frontline or relapsed/refractory higher-risk CLL: pooled analysis of 5 clinical trialsMatthew S Davids, Jeff P Sharman, Paolo Ghia, et al.
British Journal of Haematology|September 19, 2019
Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinibElizabeth M Kander, Qiuhong Zhao, Seema A Bhat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Pentostatin in steroid-refractory acute graft-versus-host diseaseJavier Bolaños-Meade, David A Jacobsohn, Jeffrey Margolis, et al.
Pageof 106